Amberstone Biosciences, Inc. is an early-stage biotechnology company focused on developing next-generation T cell engagers (TCEs) for the treatment of solid tumors. The company's proprietary T-MATE platform leverages the acidic environment found in tumor microenvironment to locally activate TCEs, thereby minimizing on-target toxicity and enabling the development of safer and more effective therapeutics. Amberstone is advancing a diverse pipeline of T-MATE-based therapeutics for solid tumors that are intractable with conventional TCEs. The company is headquartered in Irvine, California.
Amberstone Biosciences的外部链接
15300 Barranca Pkwy
100
US，California，Irvine，92618
#SITC2024 is starting in a week with an exciting scientific agenda and groundbreaking updates from many teams! Amberstone Biosciences will be there to exchange and connect; Yang (Alice) Zhou will be presenting a poster on our T-MATE platform, showing how the pH-gating strategy can expand the therapeutic window of #TCellEngagers. #immunotherapy #antibodies #bispecific #solidtumors #TCells
We are attending SITC 2024.
Antibody therapy | Cellular therapy | CAR engineering | T/iNKT/NK culture | Hematopoietic stem cell engineering | iPSC
I am excited to present a poster at the #SITC2024 Annual Meeting in Houston. Check it out if you are attending the conference and are interested in learning more about cutting-edge advances in cancer immunotherapy and antibody engineering! Looking forward to connecting with colleagues and discussing the latest innovations. #Oncology #AntibodyEngineering #Immunotherapy #AmberstoneBiosciences
We are attending SITC 2024.